Dinebra retroflexa Herbal Phytotherapy : A Simulation Study Based on Bleomycin-Induced Pulmonary Fibrosis Retraction Potential in Swiss Albino Rats / Atef A. El-Hela, Mostafa M. Hegazy, Hatem S. Abbass, Amal H. Ahmed, Marwa S. Abu Bakr, Rawah H. Elkousy, Adel Ehab Ibrahim, Sami El Deeb, Ossama M. Sayed and Enas S. Gad
Background and Objectives: Fibrotic lung disease is one of the main complications of many medical conditions. Therefore, the use of anti-fibrotic agents may provide a chance to prevent, or at least modify, such complication. The aim of this study was to evaluate the protective pulmonary anti-fibrotic and anti-inflammatory effects of Dinebra retroflexa. Materials and methods: Dinebra retroflexa methanolic extract and its synthesized silver nanoparticles were tested on bleomycin-induced pulmonary fibrosis. Pulmonary fibrosis was induced by intratracheal instillation of bleomycin (5 mg/5 mL/kg-Saline) as a supposed model for induced lung fibrosis. The weed evaluation was performed by intratracheal instillation of Dinebra retroflexa methanolic extract and its silver nanoparticles (35 mg/100 mL/kg-DMSO, single dose). Results: The results showed that both Dinebra retroflexa methanolic extract and its silver nanoparticles had a significant pulmonary fibrosis retraction potential, with Ashcroft scores of three and one, respectively, and degrees of collagen deposition reduction of 33.8 and 46.1%, respectively. High-resolution UHPLC/Q-TOF-MS/MS metabolic profiling and colorimetrically polyphenolic quantification were performed for further confirmation and explanation of the represented effects. Such activity was believed to be due to the tentative identification of twenty-seven flavonoids and one phenolic acid along with a phenolic content of 57.8 mg/gm (gallic acid equivalent) and flavonoid content of 22.5 mg/gm (quercetin equivalent). Conclusion: Dinebra retroflexa may be considered as a promising anti-fibrotic agent for people at high risk of complicated lung fibrosis. The results proved that further clinical trials would be recommended to confirm the proposed findings..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
Basel: MDPI ; 2022 Braunschweig: Universitätsbibliothek ; 2022 |
| Enthalten in: |
Medicina - 58 (2022) 12, p. 1719 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
El-Hela, Atef A [VerfasserIn] |
|---|
| Links: |
publikationsserver.tu-braunschweig.de [kostenfrei] |
|---|
| Themen: |
Bleomycin |
|---|
| Umfang: |
1 Online-Ressource (17 Seiten) |
|---|
| doi: |
10.3390/medicina58121719 |
|---|---|
| Weitere IDs: |
urn:nbn:de:gbv:084-2023020612497 |
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1833294440 |
|---|
| LEADER | 01000cam a2200265 4500 | ||
|---|---|---|---|
| 001 | 1833294440 | ||
| 003 | DE-627 | ||
| 005 | 20230428164927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230206s2022 sz |||||o 00| ||eng c | ||
| 024 | 7 | |a urn:nbn:de:gbv:084-2023020612497 |2 urn | |
| 024 | 7 | |a 10.3390/medicina58121719 |2 doi | |
| 035 | |a (DE-627)1833294440 | ||
| 035 | |a (DE-599)KXP1833294440 | ||
| 035 | |a (OCoLC)1369539249 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XA-CH |c XA-DE | ||
| 100 | 1 | |a El-Hela, Atef A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dinebra retroflexa Herbal Phytotherapy |b A Simulation Study Based on Bleomycin-Induced Pulmonary Fibrosis Retraction Potential in Swiss Albino Rats |c Atef A. El-Hela, Mostafa M. Hegazy, Hatem S. Abbass, Amal H. Ahmed, Marwa S. Abu Bakr, Rawah H. Elkousy, Adel Ehab Ibrahim, Sami El Deeb, Ossama M. Sayed and Enas S. Gad |
| 264 | 1 | |a Basel |b MDPI |c 2022 | |
| 264 | 2 | |a Braunschweig |b Universitätsbibliothek |c 2022 | |
| 300 | |a 1 Online-Ressource (17 Seiten) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background and Objectives: Fibrotic lung disease is one of the main complications of many medical conditions. Therefore, the use of anti-fibrotic agents may provide a chance to prevent, or at least modify, such complication. The aim of this study was to evaluate the protective pulmonary anti-fibrotic and anti-inflammatory effects of Dinebra retroflexa. Materials and methods: Dinebra retroflexa methanolic extract and its synthesized silver nanoparticles were tested on bleomycin-induced pulmonary fibrosis. Pulmonary fibrosis was induced by intratracheal instillation of bleomycin (5 mg/5 mL/kg-Saline) as a supposed model for induced lung fibrosis. The weed evaluation was performed by intratracheal instillation of Dinebra retroflexa methanolic extract and its silver nanoparticles (35 mg/100 mL/kg-DMSO, single dose). Results: The results showed that both Dinebra retroflexa methanolic extract and its silver nanoparticles had a significant pulmonary fibrosis retraction potential, with Ashcroft scores of three and one, respectively, and degrees of collagen deposition reduction of 33.8 and 46.1%, respectively. High-resolution UHPLC/Q-TOF-MS/MS metabolic profiling and colorimetrically polyphenolic quantification were performed for further confirmation and explanation of the represented effects. Such activity was believed to be due to the tentative identification of twenty-seven flavonoids and one phenolic acid along with a phenolic content of 57.8 mg/gm (gallic acid equivalent) and flavonoid content of 22.5 mg/gm (quercetin equivalent). Conclusion: Dinebra retroflexa may be considered as a promising anti-fibrotic agent for people at high risk of complicated lung fibrosis. The results proved that further clinical trials would be recommended to confirm the proposed findings. | ||
| 650 | 4 | |a Bleomycin | |
| 650 | 4 | |a Dinebra Retroflexa | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Lung | |
| 650 | 4 | |a Metal Nanoparticles | |
| 650 | 4 | |a Phytotherapy | |
| 650 | 4 | |a Pulmonary fibrosis | |
| 650 | 4 | |a Rats | |
| 650 | 4 | |a Silver | |
| 650 | 4 | |a Silver Nanoparticles | |
| 650 | 4 | |a Switzerland | |
| 650 | 4 | |a Uhplc/Qtof-Ms/Ms | |
| 700 | 1 | |a Abbass, Hatem S |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Amal H |e verfasserin |4 aut | |
| 700 | 1 | |a Bakr, Marwa S Abu |e verfasserin |4 aut | |
| 700 | 1 | |a Eldeeb, Sami |d 1976- |e verfasserin |0 (DE-588)133126293 |0 (DE-627)534964532 |0 (DE-576)29964068X |4 aut | |
| 700 | 1 | |a Elkousy, Rawah H |e verfasserin |4 aut | |
| 700 | 1 | |a Gad, Enas S |e verfasserin |4 aut | |
| 700 | 1 | |a Hegazy, Mostafa M |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim, Adel Ehab |e verfasserin |4 aut | |
| 700 | 1 | |a Sayed, Ossama M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Sonderdruck aus |t Medicina |g 58 (2022) 12, p. 1719 |x 1648-9144 |
| 856 | 4 | 0 | |u http://publikationsserver.tu-braunschweig.de/get/72143 |x Resolving-System |z kostenfrei |
| 856 | 4 | 0 | |u https://nbn-resolving.org/urn:nbn:de:gbv:084-2023020612497 |x Resolving-System |z kostenfrei |
| 912 | |a GBV_ILN_20 | ||
| 912 | |a ISIL_DE-84 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 935 | |c so | ||
| 951 | |a BO | ||
| 980 | |2 20 |1 01 |x 0084 |b 4267614490 |y z |z 06-02-23 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 4283588180 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 06-03-23 | ||
| 981 | |2 20 |1 01 |x 0084 |r http://publikationsserver.tu-braunschweig.de/get/72143 | ||
| 981 | |2 20 |1 01 |x 0084 |r https://nbn-resolving.org/urn:nbn:de:gbv:084-2023020612497 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://nbn-resolving.org/urn:nbn:de:gbv:084-2023020612497 | ||